Pediatric Neurology
Volume 29, Issue 2 , Pages 143-147 , August 2003

Topiramate concentration in saliva: an alternative to serum monitoring

  • Michael V Miles, PharmD

      Affiliations

    • Pathology and Laboratory Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA
    • Pediatrics and Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; Pharmacy Practice and Science and Neurology, Cincinnati, Ohio, USA
    • Corresponding Author InformationCommunications should be addressed to: Dr. Miles; Division of Pathology and Laboratory Medicine, Cincinnati, Children’s; Hospital Medical Center; 3333 Burnet Ave; Cincinnati, OH 45229, USA.
    • ,
  • Peter H Tang, PhD

      Affiliations

    • Pathology and Laboratory Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA
    • ,
  • Tracy A Glauser, MD

      Affiliations

    • Pediatrics and Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; Pharmacy Practice and Science and Neurology, Cincinnati, Ohio, USA
    • ,
  • Melody A Ryan, Pharm D, BCPS, CGP

      Affiliations

    • Pharmacy Practice and Science and Neurology, University of Kentucky Chandler Medical Center, Lexington, KY, USA
    • ,
  • Shellee A Grim, PharmD

      Affiliations

    • Pharmacy Practice and Science and Neurology, University of Kentucky Chandler Medical Center, Lexington, KY, USA
    • ,
  • Richard H Strawsburg, MD

      Affiliations

    • Pediatrics and Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; Pharmacy Practice and Science and Neurology, Cincinnati, Ohio, USA
    • ,
  • Ton J deGrauw, MD, PhD

      Affiliations

    • Pediatrics and Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; Pharmacy Practice and Science and Neurology, Cincinnati, Ohio, USA
    • ,
  • Robert J Baumann, MD

      Affiliations

    • Pediatrics and Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; Pharmacy Practice and Science and Neurology, Cincinnati, Ohio, USA

Received 21 November 2002 ,Accepted 21 January 2003.

References 

  1. Privitera M, Fincham R, Penry J, et al.  Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Neurology. 1996;46:1678–1683
  2. Tassinari CA, Michelucci R, Chauvel P, et al.  Double-blind, placebo-controlled trial of topiramate (600 mg) daily for the treatment of refractory partial epilepsy. Epilepsia. 1996;37:763–768
  3. Biton V, Montouris GD, Ritter F, et al.  A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology. 1999;52:1330–1337
  4. Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology. 1999;52:1338–1344
  5. Levisohn PM. Safety and tolerability of topiramate in children. J Child Neurol. 2000;15:S22–S26
  6. Wallace SJ. Newer antiepileptic drugs (Advantages and disadvantages). Brain Dev. 2001;23:277–283
  7. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH. Topiramate versus Bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder (A preliminary single-blind study). Bipolar Disorders. 2002;4:207–213
  8. Vieta E, Torrent C, Garcia-Ribas G, et al.  Use of topiramate in treatment-resistant bipolar spectrum disorders. J Clin Psychopharmacol. 2002;22:431–435
  9. Connor GS. A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology. 2002;59:132–134
  10. RozenTD. Antiepileptic drugs in the management of cluster headache and trigeminal neuralgia. Headache 2001;November/December Suppl:S25-S32
  11. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention (A double-blind placebo-controlled study). Headache. 2001;41:968–976
  12. Appolinario JC, Fontenelle LF, Papelbaum M, Bueno JR, Coutinho W. Topiramate use in obese patients with binge eating disorder (An open study). Can J Psychiatry. 2002;47:271–273
  13. Perucca E. Is there a role for therapeutics drug monitoring of new anticonvulsants?. Clin Pharmacokinet. 2000;38:191–204
  14. May TW, Rambeck B, Jürgens U. Serum concentrations of topiramate in patients with epilepsy (Influence of dose, age, and comedication). Ther Drug Monit. 2002;24:366–374
  15. Contin M, Riva R, Albani F, Avoni P, Baruzzi A. Topiramate therapeutic monitoring in patients with epilepsy (Effect of concomitant antiepileptic drugs). Ther Drug Monit. 2002;24:332–337
  16. Schwabe MJ, Wheless JW. Clinical experience with topiramate dosing and serum levels in children 12 years or under with epilepsy. J Child Neurol. 2001;16:806–808
  17. Tomson T, Johannessen SI. Therapeutic monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol. 2000;55:697–705
  18. Penovich PE, Schroeder-Gustafson M, Gates JR, Moriarty GL. Clinical experience with topiramate (Correlation of serum levels with efficacy and adverse events). Epilepsia. 1997;38(Suppl. 8):181
  19. Petroff OAC, Hyder F, Rothman DL, Mattson RH. Topiramate rapidly raises brain γ-aminobutyric acid in epilepsy patients. Epilepsia. 2001;42:543–548
  20. Kuzniecky R, Ho S, Pan J, et al.  Modulation of cerebral γ-aminobutyric acid by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology. 2002;58:368–372
  21. Christensen J, Højskov CS, Dam M, Poulsen JH. Plasma concentration of topiramate correlates with cerebrospinal fluid concentration. Ther Drug Monit. 2001;23:529–535
  22. Sachdeo RC, Sachdeo SK, Levy RH, et al.  Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia. 2002;43:691–696
  23. Öhman I, Vitols S, Luef G, Söderfeldt B, Tomsona T. Topiramate kinetics during delivery, lactation, and in the neonate (Preliminary observations). Epilepsia. 2002;43:1157–1160
  24. Snodgrass SR, Vedanarayanan VV, Parker CC, Parks BR. Pediatric patient with undetectable anticonvulsant blood levels (Comparison with compliant patients). J Child Neurol. 2001;16:164–168
  25. Drobitch RK, Svensson CK. Therapeutic drug monitoring in saliva (An update). Clin Pharmacokinet. 1992;23:365–379
  26. Gorodischer R, Burtin P, Hwang P, Levine M, Koren G. Saliva verses blood sampling for therapeutic drug monitoring in children (Patient and parental preferences and an economic analysis). Ther Drug Monit. 1994;16:437–443
  27. Liu H, Delgato MR. Therapeutic drug concentration monitoring using saliva samples. Clin Pharmacokinet. 1999;36:453–470
  28. Tang PH, Miles MV, Glauser TA, et al.  An improved gas chromatography assay for topiramate monitoring in pediatric patients. Ther Drug Monit. 2000;22:195–201
  29. Glauser TA, Clark PO, McGee K. Long-term response to topiramate in patients with West syndrome. Epilepsia. 2000;41(Suppl. 1):S91–S94
  30. Thijs J, Verhelst H, Van Coster R. Retrospective study of topiramate in a paediatric population with intractable epilepsy showing promising effects in the West syndrome patients. Acta Neurol Belg. 2001;101:171–176
  31. Rosenfeld WE, Doose DR, Walker SA, Baldassarree JS, Reife RA. A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr Neurol. 1999;20:339–344
  32. Glauser TA, Miles MV, Tang P, Clark P, McGee K, Doose DR. Topiramate pharmacokinetics in infants. Epilepsia. 1999;40:788–791
  33. Login E, Teich M, Koelfen W. König S. Topiramate enhances the risk of valproate-associated side effects in three children. Epilepsia. 2002;43:451–454
  34. Mack CJ, Kuc S, Mulcrone SA, Pilley A, Grünewald RA. Interaction of topiramate with carbamazepine (Two case reports and a review of clinical experience). Seizure. 2002;11:464–467

PII: S0887-8994(03)00048-1

doi: 10.1016/S0887-8994(03)00048-1

Pediatric Neurology
Volume 29, Issue 2 , Pages 143-147 , August 2003

Article Tools

* Image Usage & Resolution